Kotobuki Pharmaceutical Co Ltd
Kotobuki Pharmaceutical Co., Ltd., commonly referred to as Kotobuki Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan (JP). Established in 1948, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, particularly in the fields of prescription medications and over-the-counter solutions. With a strong operational presence across Asia, Kotobuki Pharma is renowned for its innovative approach to drug formulation and delivery systems. The company’s core offerings include a diverse range of therapeutic agents that address various health conditions, setting them apart through their commitment to quality and efficacy. Kotobuki Pharmaceutical has achieved notable recognition within the industry, solidifying its market position through strategic partnerships and a robust research and development framework. As a trusted name in healthcare, Kotobuki Pharma continues to contribute to the well-being of communities both locally and internationally.
DitchCarbon Score
How does Kotobuki Pharmaceutical Co Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kotobuki Pharmaceutical Co Ltd's score of 3 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kotobuki Pharmaceutical Co Ltd's reported carbon emissions
In 2017, Kotobuki Pharmaceutical Co Ltd reported total carbon emissions of approximately 283,000,000 kg CO2e across all scopes. This included about 87,000,000 kg CO2e from Scope 1, 119,000,000 kg CO2e from Scope 2, and a significant 283,000,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown revealed major contributions from purchased goods and services (approximately 144,418,000 kg CO2e) and business travel (about 32,572,000 kg CO2e). In 2019, the company’s emissions were notably lower, with Scope 1 emissions at approximately 6,760,000 kg CO2e and Scope 2 emissions at about 40,000,000 kg CO2e. By 2020, Scope 1 emissions decreased further to around 6,490,000 kg CO2e, while Scope 2 remained stable at 40,000,000 kg CO2e. However, Scope 3 emissions were reported at approximately 1,720,000,000 kg CO2e, primarily driven by purchased goods and services. Despite these figures, Kotobuki Pharmaceutical has not publicly disclosed specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests a need for enhanced transparency and strategic planning in their sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2019 | 2020 | |
|---|---|---|---|
| Scope 1 | 87,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | 119,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 283,000,000 | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kotobuki Pharmaceutical Co Ltd is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
